WallStSmart
ELDN

Eledon Pharmaceuticals Inc

NASDAQ: ELDN · HEALTHCARE · BIOTECHNOLOGY

$3.88
-6.12% today

Updated 2026-06-02

Market cap
$263.21M
P/E ratio
P/S ratio
EPS (TTM)
$-0.77
Dividend yield
52W range
$1 – $5
Volume
1.4M

Eledon Pharmaceuticals Inc (ELDN) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-77.79%
ROA
-35.10%
Debt/equity
0.01x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2012$-9.65M
2013$-15.72M
2014$-23.30M
2015$-45.09M
2016$-37.96M
2017$0.00$-13.12M
2018$0.00$-14.06M
2019$0.00$-16.01M
2020$120000.00$-22.81M-152.50%-15,387.50%-19,009.17%
2021$120000.00$-34.51M100.00%-30,722.50%-28,755.00%
2022$0.00$-87.97M
2023$0.00$-40.33M
2024$0.00$-36.18M
2025$0.00$-45.62M

Frequently asked questions

How much free cash flow does ELDN generate?

ELDN produced $-62.34M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ELDN's balance sheet healthy?

ELDN holds $22.81M in cash and equivalents against — in long-term debt, on $81.08M of shareholder equity. That debt is best read against the cash flow the business throws off each year.